Identify the mechanism
Use lipid species, flux measurements and tissue context to establish whether new synthesis, recycling or disposal is altered.
MYRIOCIN · SPHINGOLIPIDS · SPORADIC ALS
Can changing a lipid pathway
change ALS?
A fungal molecule. A cellular bottleneck. A promising question with a more complicated answer than “less is better.”
Sphingolipid metabolism is altered in sporadic ALS as well as rare genetic forms. But an elevated lipid level does not tell us why it rose—or whether suppressing its production will help.
BIOLOGICAL RATIONALE CredibleHUMAN BENEFIT Unproven
ONE PATHWAY. DIFFERENT DESTINATIONS.
CONCEPTUAL PATHWAY ILLUSTRATION · NOT A MOLECULAR STRUCTURE
01 / THE SHORT ANSWER
A plausible target
for a subset.
An unanswered
clinical question.
Could it extend beyond rare genetic ALS? Possibly. Human sporadic ALS studies implicate this pathway, and a model of disrupted lipid disposal responds to SPT inhibition.
That supports testing the idea. It does not establish that sporadic ALS is generally caused by excessive SPT activity, that lowering all sphingolipids is protective, or that myriocin prevents or slows ALS in people.
PATHWAY INVOLVEMENTSupportedHuman tissue, blood and disease models.
RIGHT TARGET FOR EVERYONENot establishedSpecies, compartment and disease stage matter.
PREVENTION OR SLOWINGUnproven in peopleA treatment trial cannot yet answer prevention.
02 / FOLLOW THE PATHWAY
These fats do
more than one job.
Sphingolipids help build membranes, support myelin and organize cellular signals. Some intermediates can also become harmful in a particular context. Click a step to follow the biology.
SERINE + PALMITOYL-CoA
↓
↓
→
↓
01
SPT controls new entry.
Serine palmitoyltransferase starts de novo sphingolipid synthesis. In some rare ALS variants, normal feedback control is disrupted and this entry flux rises. Myriocin inhibits the enzyme.
In sporadic ALS, a high measured lipid concentration does not by itself establish that this enzyme is overactive.
Read the primary study ↗Simplified biology. Intermediates, species-specific enzymes and organelle transport are omitted. The simulation below makes a further abstraction.
03 / WHAT THE STUDIES SAY
The evidence points
in several directions.
Human observations make the pathway relevant. Experiments reveal why the direction of an intervention still needs to be tested.
04 / THE INTERACTIVE LAB
Change the gate.
Watch the trade-off.
A reproducible mass-balance model explores different explanations for altered lipid pools. It calculates pathway behavior—not ALS risk, a dose or a patient outcome.
CHOOSE A MECHANISM
Inspect the assumptions
These values explore hypotheses; they are not estimated human ALS parameters. Changing an input does not establish that it is changeable safely in a person.
NORMALIZED LIPID POOL
Ceramide-like intermediate
Paired controlSPT reductionAssumed reference
What a lower curve cannot tell you. Lowering a simulated intermediate is not evidence of neuronal survival. Lowering an essential downstream pool may be undesirable. This model deliberately has no “benefit,” survival or ALS-risk score.
05 / THE HIDDEN VARIABLE
The same starting level.
A different response.
A concentration is a snapshot. It does not identify how much comes from new synthesis versus an alternative input. This is one reason blood lipid levels cannot select an SPT treatment by themselves.
A SECOND COMPUTATIONAL EXPERIMENTHold total input constant.
Hold total input constant.
Change where it comes from.
Both synthetic systems start at the same steady-state pools. SPT reduction can still have very different effects when a different share of input bypasses SPT.
06 / STRESS-TEST THE ASSUMPTIONS
One result is easy.
Robustness is harder.
The batch experiments vary inputs and turnover rather than pretending every person has the same pathway. Their ranges describe an assumed parameter space, not a probability of clinical benefit.
Loading the reproducible batch experiments…
07 / FROM A PATHWAY TO A TREATMENT
What would make
this actionable?
Slowing diagnosed disease and preventing future ALS are different scientific questions. Neither can be answered by a pathway animation or an unvalidated biomarker change.
Show relevant exposure
Measure whether a defined molecule reaches the intended human tissue and changes its target at a tolerable exposure.
Preserve function
Test motor-neuron survival, glial effects and functioning connections to muscle—not just a fall in a lipid concentration.
Test clinical benefit
Use controlled treatment trials. Prevention would need its own prospective design, risk population and long-term safety evidence.
THE WORKING CONCLUSIONWorth testing in a defined subgroup.
Worth testing in a defined subgroup.
Too early to use for prevention.
Myriocin is a research tool with potent biological effects. Mushroom preparations, purified myriocin and fungal-inspired medicines are different exposures. The evidence does not establish an ALS-prevention supplement or a safe, effective self-treatment.
08 / MAKE IT AUDITABLE
Open the
black box.
The code, assumptions and source distinctions are part of the result. Every simulation on this page can be reproduced without personal or controlled clinical data.
Download the research package ↓The equations
dB/dt = SPT × (1 − inhibition) + alternative input
+ recycled G − conversion B→C − loss BdC/dt = conversion B→C − conversion C→G − loss CdG/dt = conversion C→G − turnover GB, C and G are simplified, dimensionless pools. G represents one complex-lipid proxy, not every beneficial sphingolipid. Parameterization, recycling and the assumed reference levels are documented in the downloadable model description.
What is measured, and what is assumed?
Study sample sizes, experimental directions and registry status are published or registered observations. Model rate constants, reference thresholds and the mapping from literature mechanisms to synthetic scenarios are assumptions. No human myriocin response, clinical efficacy or prevention risk has been estimated.
Numerical checks and reproducibility
Loading validation results…
Numerical agreement verifies implementation, not biological validity. A stable differential-equation solution is not a validated ALS model.
Download the browser model ↗Important boundaries
Blood, cerebrospinal fluid, whole spinal cord, membrane subdomains and muscle measure different compartments. Postmortem tissue can reflect advanced disease and cell loss. Lipid species can move in opposite directions. Neither an association nor Mendelian-randomization terminology alone identifies a treatment effect.
09 / GO TO THE ORIGINALS
The source
trail.
Original experiments, human studies and the official trial record. Research cutoff: November 10, 2026. Registry dates and access limits are retained in the research package.